Supernus Pharmaceuticals Inc

0.00 (0.00%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.69B
Current PE13.29
Forward PE 26.56
2yr Forward PE 21.68
See more stats
Estimates Current Quarter
Revenue$129.2 Million
Adjusted EPS$0.29
See more estimates
10-Day MA$29.97
50-Day MA$27.98
200-Day MA$24.31
See more pivots

Supernus Pharmaceuticals, Inc. Stock, NASDAQ:SUPN

9715 Key West Avenue, Rockville, Maryland 20850
United States of America
Phone: +1.301.838.2500
Number of Employees: 464


Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy. The firm also develops product candidates for the treatment of impulsive aggression and for the treatment of attention deficit hyperactivity disorder. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.